MaxCyte Welcomes Cynthia Collins to the Board of Directors
MaxCyte, Inc., a renowned player in cell engineering, has expanded its leadership team by appointing Cynthia Collins as a non-executive director. Her appointment comes as the company aims to further enhance its offerings in cell-based therapeutics and bioprocessing solutions.
Cynthia Collins: An Industry Veteran
Cynthia Collins brings an impressive background of over 40 years in biotechnology and cell therapy. Previously serving as the CEO of Editas Medicine, she played a pivotal role in pioneering in-vivo gene modified therapies that marked significant milestones in the industry. Her extensive leadership experience extends to roles at Human Longevity Inc. and General Electric Healthcare, where she managed cell therapy and lab businesses.
A Commitment to Advancing Cell Therapies
Collins is excited about her new position at MaxCyte, stating that she sees exceptional work being done to propel cell and genetic medicine forward. Her dedication to innovation aligns with MaxCyte’s mission to provide empowering technologies to developers of cell therapies. She believes her experience will be valuable in promoting the company’s objectives.
The Growing Board and Company Vision
With Collins' addition, MaxCyte's Board of Directors now comprises 10 members, each contributing diverse expertise to the company's strategic direction. Maher Masoud, President and CEO, emphasized the importance of Collins' vast knowledge in supporting their growth as a leading cell engineering platform.
MaxCyte's Technological Edge
MaxCyte has more than two decades of experience in advancing cell therapy technology. The company’s ExPERT™ platform is at the forefront of this evolution, designed to support various stages of cell therapy development, from initial discoveries to commercial applications. This platform includes a suite of sophisticated instruments and proprietary technology aiming to enhance therapeutic breakthroughs.
Regulatory Disclosures and Leadership Structure
In compliance with UK regulations, it is disclosed that Collins has held significant directorships in numerous healthcare firms, reflecting her distinguished career. Currently, she serves on several boards, including Alanis Therapeutics and Certara, showing her influential presence across the sectors.
Future Implications for MaxCyte
As MaxCyte continues to innovate and refine its processes, the guidance and insight provided by Cynthia Collins will undoubtedly play a crucial role in shaping their future. Her strategic leadership will support the company’s mission to assist developers in bringing revolutionary therapies to market.
Frequently Asked Questions
What position has Cynthia Collins been appointed to at MaxCyte?
Cynthia Collins has been appointed as a non-executive director on MaxCyte's Board of Directors.
What experience does Cynthia Collins bring to MaxCyte?
She has over 40 years of experience in the biotechnology industry, including leadership roles at Editas Medicine and Human Longevity Inc.
How many members are there on MaxCyte's Board now?
With Collins' appointment, MaxCyte's Board now consists of 10 members.
What is the ExPERT™ platform?
The ExPERT™ platform is MaxCyte's advanced technology designed to support the development and commercialization of next-generation cell therapies.
What is the strategic goal for MaxCyte with Collins on the board?
The goal is to leverage her expertise to drive growth and innovation in the field of cell and genetic medicine.
